Development and Validation of the HPLC Method for Quantification of the Innovative Drug DD217, Factor Xa Inhibitor, in Rat Plasma for a Pharmacokinetic Study

Development and Validation of the HPLC Method for Quantification of the Innovative Drug DD217, Factor Xa Inhibitor, in Rat Plasma for a Pharmacokinetic Study

Introduction. Nowadays, discovery and development of innovative drugs represent a relevant goal for the pharmaceutical market. One of such drugs is N-(5-chloropyridine-2-yl)-2-({4-[ethanimidoyl(methyl)benzoyl}amino)-5-methylbenzamide hydrochloride (hereinafter DD217), an innovative drug that belongs...

Full description

Bibliographic Details
Main Authors: N. S. Dubovik, D. F. Guranda, G. V. Ramenskaya, D. G. Tovbin, D. N. Tarasov, A. Yu. Savchenko, V. S. Arnautov
Format: Article
Language:Russian
Published: LLC Center of Pharmaceutical Analytics (LLC «CPHA») 2022-05-01
Series:Разработка и регистрация лекарственных средств
Subjects:
dd217
крысы
плазма
вэжх-мс/мс
валидация
фармакокинетика
Online Access:https://www.pharmjournal.ru/jour/article/view/1235

Similar Items

Similar Items